Integrated Peptide Drug Substance & Injectable Drug Products
Peptide Platform: Scaling Innovation from Grams to Metric Tons
Peptides have rapidly moved to the forefront of modern therapeutics, and we at CordenPharma have made bold commitments to ensure our customers have the scale, reliability, and innovation needed to succeed. Over the past year, we have initiated large expansions in our global peptide platform to respond to customers’ demand and reinforce our position as the market leader in fully integrated peptide supply.
In our CordenPharma Colorado site, we continue to undergo major expansions by adding new large-scale manufacturing lines and a greenfield facility that will more than double our Solid Phase Peptide Synthesis (SPPS) capacity to over 42,000 L by 2028, positioning it among the largest peptide production sites worldwide. In parallel, CordenPharma continues to evaluate strategic acquisition opportunities to further enhance our peptide capabilities, ensuring alignment with our long-term growth strategy.
To complement our large-scale injectable capabilities, our Frankfurt Peptide Centre of Excellence has added 1,000 m² of GMP space for early-phase API production, from grams to kilograms. By linking Frankfurt directly with our Caponago, Italy and Plankstadt, Germany facilities for sterile injectables and oral peptides respectively, we provide customers with a seamless path from API to finished dosage forms for first-in-human trials. This integrated peptide-injectable-OSD offering accelerates the time-to-market and enables customers to benefit from a single CDMO relationship while also accessing API route selection, solubility studies, characterization, reference standard qualification, formulation development, analytical method development and validation, and technical writing support for IND/IMPD submissions.
Dr. Mimoun Ayoub presents on Tag-Assisted Peptide Synthesis (TAPS) at Tides US 2025.
API Development & Innovation Award – Tag-Assisted Peptide Synthesis (TAPS)
CordenPharma is pleased to announce we won a CPHI 2025 Pharma Award for API Development & Innovation with our TAPS technology. Here, Dr. Mimoun Ayoub, Global Head of Peptides & Oligonucleotides Platforms, is joined by our CordenPharma Frankfurt peptide development team to accept the award on 28 October 2025.
CordenPharma’s Tag-Assisted Peptide Synthesis (TAPS) is a next-generation technology revolutionizing peptide manufacturing to meet the growing demand for scalable and sustainable peptide outsourcing. Indeed, the global peptide therapeutics market is expanding rapidly, driven by biologically active peptides like GLP-1 analogues. However, current manufacturing technologies, particularly SPPS, are resource-intensive, environmentally burdensome, and limited in worldwide production capacity.
TAPS solves this by combining the control of SPPS with the scalability of LPPS, eliminating resin use, reducing solvent consumption by over 90% and substantially reducing the amount of raw materials used. The peptide remains in the organic phase via a patented TAG-anchor molecule while impurities and excess amino-acid derivatives or reagents are extracted into the aqueous phase. This allows for continuous solution-phase synthesis with simple aqueous workups. The organic phase is then carried over for the next coupling and cleavage cycle.
Compared to SPPS, TAPS improves efficiency, sustainability, and scale. It eliminates resin handling, drastically cuts solvent use, and simplifies purification. Unlike LPPS, TAPS retains precise stepwise control, allowing full compatibility with SPPS reagents and know-how.
TAPS provides a greener, more economical alternative that integrates into existing small-molecule assets, enabling broad application without investment in peptide-specific hardware. This innovation opens the door for automation, modular synthesis (fragment approaches), and green manufacturing practices. It directly supports pharmaceutical trends toward flexible, scalable production of complex, high-value APIs under increasing regulatory scrutiny.
Download Our Peptide & Injectable Brochures
